Latest profit margin for Standard BioTools: 208.4% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
The latest profit margin for LAB is 208.4% as of September 2026. That compares with -99.55% in the prior-year period — up 309.3% year over year. That is above the Healthcare sector average of 17.63%. Investors often review this figure alongside Standard BioTools's historical trend and sector peers before judging valuation or financial health.
Over the past year, LAB's profit margin moved from -99.55% to 208.4% — a 309.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Standard BioTools's valuation or profitability profile.
Against Healthcare companies, LAB currently prints 208.4% for profit margin, while the sector average sits near 17.63%. That is roughly 1082.2% above the sector mean. Large gaps often invite a closer look at Standard BioTools's growth, margins, and balance sheet.
Profit Margin shows how effectively Standard BioTools converts resources into returns. At 208.4%, LAB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -99.55% in the prior-year period — up 309.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting LAB's profit margin (208.4%), review year-over-year change from -99.55%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.